Abstract 466P
Background
The daycare caters to numerous cancer patients. Patient satisfaction is a surrogate estimator of the quality of healthcare. Determination of the factors responsible for this will help to improve patient care delivery.
Methods
Women with breast or ovarian malignancies undergoing chemotherapy at the medical oncology daycare unit from 1st January 2023 to 1st April 2023 were invited to complete the PSS questionnaire anonymously. The PSS tool is an abbreviated 28 item questionnaire related to administrative services, medical team members and the treating consultant. The response options comprised a 5-point Likert scale. The raw scores were linearly transformed to a 0-100 scale and patients scoring more than 60 were considered as satisfied.
Results
A total of 117 patients participated in the study. There was a high level of overall satisfaction rate (93.2%). Availability of social support and health insurance were significant determinants of patient satisfaction (p=0.0043 and p=0.0006 respectively). The median waiting time was 3 hours with a satisfaction rate of 84%. The satisfaction rate for secretarial assistance, medical staff and the treating physician were 94%, 94% and 93.2% respectively. The patients’ likelihood of returning to our daycare for and recommending it to others were 97.4% and 96.6% respectively.
Conclusions
Ensuring availability of social support, provision of health insurance and effective patient-physician communication is likely to increase patient satisfaction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract